

---

**BIOMEDICAL RESEARCH FOUNDATION OF**  
**NORTHWEST LOUISIANA**

**CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2009**

---

Under provisions of state law, this report is a public document. A copy of the report has been submitted to the entity and other appropriate public officials. The report is available for public inspection at the Baton Rouge office of the Legislative Auditor and, where appropriate, at the office of the parish clerk of court.

Release Date

9/1/10



Postlethwaite  
& Netterville

A Professional Accounting Corporation

[www.pncpa.com](http://www.pncpa.com)

**BIOMEDICAL RESEARCH FOUNDATION OF**  
**NORTHWEST LOUISIANA**

**CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2009**

## **TABLE OF CONTENTS**

	<b><u>Page</u></b>
<b><u>Independent Auditors' Report</u></b>	<b>1</b>
<b><u>Financial Statements</u></b>	
Consolidated Statements of Financial Position	2
Consolidated Statements of Activities	3 - 4
Consolidated Statements of Cash Flows	5
Notes to Consolidated Financial Statements	6 - 20
<b><u>Governmental Audit Reports</u></b>	
Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With <i>Government Auditing Standards</i>	21 - 22
Independent Auditors' Report on Compliance with Requirements Applicable to Each Major Program and on Internal Control Over Compliance in Accordance With OMB Circular A-133	23 - 24
Schedule of Expenditures of Federal Awards	25 - 6
Schedule of Findings and Questioned Costs	27 - 28
Summary Schedule of Prior Year Findings and Questioned Costs	29



A Professional Accounting Corporation  
Associated Offices in Principal Cities of the United States  
www.pncpa.com

## INDEPENDENT AUDITORS' REPORT

Board of Directors  
Biomedical Research Foundation of Northwest Louisiana  
Shreveport, Louisiana

We have audited the accompanying consolidated statements of financial position of the Biomedical Research Foundation of Northwest Louisiana and its subsidiaries (the Foundation) as of December 31, 2009 and 2008, and the related consolidated statements of activities and cash flows for the years then ended. These financial statements are the responsibility of the Foundation's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. An audit includes consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Biomedical Research Foundation of Northwest Louisiana and its subsidiaries as of December 31, 2009 and 2008, and the results of their operations and their cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

In accordance with *Government Auditing Standards*, we have also issued our report dated April 28, 2010, on our consideration of the Foundation's internal control over financial reporting and our tests of its compliance with certain provisions of laws, regulations, contracts, grant agreements, and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* and should be read in conjunction with this report in considering the results of our audits.

*Postlethwaite : Netterville*

Baton Rouge, Louisiana  
April 28, 2010

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**CONSOLIDATED STATEMENTS OF FINANCIAL POSITION**  
**DECEMBER 31, 2009 AND 2008**

**ASSETS**

	<u>2009</u>	<u>2008</u>
Cash and cash equivalents	\$ 1,466,187	\$ 1,061,860
Restricted cash and cash equivalents	523,264	823,460
Unconditional promises to give, net	268,093	224,093
Accounts receivable, net of allowances for doubtful accounts of \$222,672 and \$332,189, respectively	1,388,964	1,474,420
Prepaid expenses and other	107,887	140,429
Bond issuance costs	122,302	165,384
Investments, including \$1,808,781 and \$1,840,953 restricted for endowment purposes	5,541,181	3,940,002
Property and equipment, net	50,333,158	51,638,833
Total assets	<u>\$ 59,751,036</u> ✓	<u>\$ 59,468,481</u>

**LIABILITIES AND NET ASSETS**

**LIABILITIES**

Accounts payable and accrued expenses	\$ 845,637	\$ 1,249,192
Line-of-credit	-	266,827
Notes payable	471,717	836,354
Revenue bonds payable, net of discount	11,316,736	12,755,200
Annuities payable	31,026	38,526
Asset retirement liability	89,056	89,056
Total liabilities	<u>12,754,172</u>	<u>15,235,155</u>

**NET ASSETS**

Unrestricted	44,898,411	41,800,492
Temporarily restricted	289,672	591,881
Permanently restricted	1,808,781	1,840,953
Total net assets	<u>46,996,864</u>	<u>44,233,326</u>
Total liabilities and net assets	<u>\$ 59,751,036</u> ✓	<u>\$ 59,468,481</u>

The accompanying notes are an integral part of these statements.

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**CONSOLIDATED STATEMENT OF ACTIVITIES**  
**YEAR ENDED DECEMBER 31, 2009**

	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Permanently Restricted</u>	<u>Total</u>
<b>REVENUES AND SUPPORT:</b>				
Support - philanthropic	\$ 169,550	\$ 163,133	\$ 100	\$ 332,783
Rental revenues	4,189,919	-	-	4,189,919
Local government operating grants	2,275,001	-	-	2,275,001
Federal and state grants and contracts	1,423,771	-	-	1,423,771
Investment revenues (losses)	1,454,029	-	-	1,454,029
Positron Emission Tomography (PET)	5,685,984	-	-	5,685,984
Radiopharmaceutical sales	1,599,745	-	-	1,599,745
	<u>16,797,999</u>	<u>163,133</u>	<u>100</u>	<u>16,961,232</u>
Net assets released from restrictions:				
Restrictions satisfied by payments	465,342	(465,342)	-	-
Withdrawal of donor restrictions	32,272	-	(32,272)	-
Total revenues and support	<u>17,295,613</u>	<u>(302,209)</u>	<u>(32,172)</u>	<u>16,961,232</u>
<b>EXPENSES:</b>				
Program services:				
Scientific research initiatives:				
Grants and support for scientific investigators	734,385	-	-	734,385
Leased research facilities	2,551,419	-	-	2,551,419
Science park development initiatives:				
Land, infrastructure, and program development and marketing	3,192,845	-	-	3,192,845
Grants, loans, and financial activities	38,616	-	-	38,616
Positron Emission Tomography (PET) and Radiopharmaceutical Distribution	5,629,819	-	-	5,629,819
Other sponsored projects	313,415	-	-	313,415
Total program services	<u>12,460,499</u>	<u>-</u>	<u>-</u>	<u>12,460,499</u>
Support services:				
Management and general	1,546,618	-	-	1,546,618
Fund-raising	190,577	-	-	190,577
Total expenses	<u>14,197,694</u>	<u>-</u>	<u>-</u>	<u>14,197,694</u>
<b>CHANGE IN NET ASSETS</b>	<u>3,097,919</u>	<u>(302,209)</u>	<u>(32,172)</u>	<u>2,763,538</u>
Net assets - beginning of year	<u>41,800,492</u>	<u>591,881</u>	<u>1,840,953</u>	<u>44,233,326</u>
<b>Net assets - end of year</b>	<u><u>\$ 44,898,411</u></u>	<u><u>\$ 289,672</u></u>	<u><u>\$ 1,808,781</u></u>	<u><u>\$ 46,996,864</u></u>

The accompanying notes are an integral part of this statement.

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**CONSOLIDATED STATEMENT OF ACTIVITIES**  
**YEAR ENDED DECEMBER 31, 2008**

	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Permanently Restricted</u>	<u>Total</u>
<b>REVENUES AND SUPPORT:</b>				
Support - philanthropic	\$ 27,250	\$ 194,977	\$ 337,205	\$ 559,432
Rental revenues	4,072,861	-	-	4,072,861
Local government operating grants	2,250,000	-	-	2,250,000
Federal and state grants and contracts	1,365,727	-	-	1,365,727
Investment revenues (losses)	(1,765,811)	-	-	(1,765,811)
Positron Emission Tomography (PET)	5,527,422	-	-	5,527,422
Radiopharmaceutical sales	1,295,350	-	-	1,295,350
	<u>12,772,799</u>	<u>194,977</u>	<u>337,205</u>	<u>13,304,981</u>
Net assets released from restrictions:				
Restrictions satisfied by payments	1,367,373	(1,367,373)	-	-
Change in donor restrictions	309,250	-	(309,250)	-
Total revenues and support	<u>14,449,422</u>	<u>(1,172,396)</u>	<u>27,955</u>	<u>13,304,981</u>
<b>EXPENSES:</b>				
Program services:				
Scientific research initiatives:				
Grants and support for scientific investigators	976,690	-	-	976,690
Leased research facilities	2,554,518	-	-	2,554,518
Science park development initiatives:				
Land, infrastructure, and program development and marketing	3,290,447	-	-	3,290,447
Grants, loans, and financial activities	90,794	-	-	90,794
Positron Emission Tomography (PET) and Radiopharmaceutical Distribution	5,530,414	-	-	5,530,414
Other sponsored projects	1,140,366	-	-	1,140,366
Total program services	<u>13,583,229</u>	<u>-</u>	<u>-</u>	<u>13,583,229</u>
Support services:				
Management and general	1,461,923	-	-	1,461,923
Fund-raising	201,184	-	-	201,184
Total expenses	<u>15,246,336</u>	<u>-</u>	<u>-</u>	<u>15,246,336</u>
<b>CHANGE IN NET ASSETS</b>	<b>(796,914)</b>	<b>(1,172,396)</b>	<b>27,955</b>	<b>(1,941,355)</b>
Net assets - beginning of year	<u>42,597,406</u>	<u>1,764,277</u>	<u>1,812,998</u>	<u>46,174,681</u>
Net assets - end of year	<u>\$ 41,800,492</u>	<u>\$ 591,881</u>	<u>\$ 1,840,953</u>	<u>\$ 44,233,326</u>

The accompanying notes are an integral part of this statement.

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**YEARS ENDED DECEMBER 31, 2009 AND 2008**

	<u>2009</u>	<u>2008</u>
<b><u>CASH FLOWS FROM OPERATING ACTIVITIES</u></b>		
Change in net assets	\$ 2,763,538	\$ (1,941,355)
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Depreciation and amortization	2,299,462	2,266,766
Loss (gain) on sales of investments	583,200	(2,727)
(Increase) decrease in unrealized gain on investments	(1,643,183)	2,268,678
(Increase) decrease in accounts receivable	41,456	(447,445)
Decrease in prepaid expenses and other assets	32,542	52,280
Increase (decrease) in accounts payable and other liabilities	(411,055)	498,521
Net cash provided by operating activities	<u>3,665,960</u>	<u>2,694,718</u>
<b><u>CASH FLOWS FROM INVESTING ACTIVITIES</u></b>		
Purchases of property and equipment	(934,169)	(1,045,317)
Purchase of investments	(1,826,158)	(1,041,277)
Proceeds from sales of investments	1,284,962	224,951
Net cash used in investment activities	<u>(1,475,365)</u>	<u>(1,861,643)</u>
<b><u>CASH FLOWS FROM FINANCING ACTIVITIES</u></b>		
Net increase (decrease) in line-of-credit	(266,827)	266,827
Payments on revenue bonds	(1,455,000)	(1,355,000)
Payments on notes payables	(364,637)	(1,278,018)
Net cash used in financing activities	<u>(2,086,464)</u>	<u>(2,366,191)</u>
Net increase (decrease) in cash and cash equivalents	104,131	(1,533,116)
Cash and cash equivalents - beginning of year	<u>1,885,320</u>	<u>3,418,436</u>
Cash and cash equivalents - end of year	<u>\$ 1,989,451</u>	<u>\$ 1,885,320</u>
<b><u>Supplemental disclosure of cash flow information:</u></b>		
Cash paid during the year for interest	<u>\$ 1,044,308</u>	<u>\$ 1,118,668</u>

The accompanying notes are an integral part of these statements.



**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**I. Summary of activities and accounting policies**

The accounting and reporting policies of the Biomedical Research Foundation of Northwest Louisiana (the Foundation) conform to the accounting principles generally accepted in the United States of America and the prevailing practices within the non-profit industry. A summary of significant accounting policies is as follows:

**Organization**

The Foundation is a publicly supported not-for-profit organization which was created to pioneer a knowledge-based regional economy by cultivating and attracting life science enterprises and related technologies. The Foundation promotes and develops (1) private and public support and collaboration for a knowledge-based economic development strategy, (2) InterTech Park as a suitable physical environment for life science enterprises and related technologies, (3) capacities and accomplishments, in collaboration with and support of, LSU Health Sciences Center in Shreveport (LSUHSC-S), (4) human resources and regional knowledge base via K-12, higher education, and technical / professional training programs, and (5) support and resources for technology and business innovation, with people, research, facilities, and funding.

**Consolidation**

The consolidated financial statements include the accounts of the Biomedical Research Foundation of Northwest Louisiana and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

The Foundation owns 100% of Intertech Venture Fund, LP (the Fund or the Partnership) through its two wholly owned subsidiaries, InterTech Venture Management, LLC (VC Management) and BRF Capital, LLC (Capital). VC Management functions as the general partner in the Fund, and Capital operates as the limited partner. The operations of the subsidiaries and the Fund are included in these consolidated financial statements. The Fund was formed to provide venture capital to new businesses desiring to locate in Northwest Louisiana.

During the year ended December 31, 2001, the Foundation formed Southern Isotopes, LLC, a wholly owned subsidiary, to operate a cyclotron in South Louisiana.

**Use of estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

**Restricted cash and cash equivalents**

Restricted cash and cash equivalents, which consist primarily of money market funds and short-term certificates of deposit, represent donor-restricted assets, assets held by the trustee under the bond indenture agreement, and assets pledged for future decommissioning expenses at its two cyclotron sites.

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

1. **Summary of activities and accounting policies (continued)**

**Accounts receivable**

The Foundation maintains an allowance for doubtful accounts based on management's assessment of collectibility, current economic conditions, and prior experience. The Foundation uses historical collection percentages for each type of payor to determine the allowance; these amounts are reviewed on an annual basis.

The Foundation determines if receivables are past-due based on the contractual terms of the sales agreement and accrues interest on past-due accounts. The Foundation charges off receivables if management considers the collection of the outstanding balance to be doubtful.

**Investments**

Investments in equity securities with readily determinable fair values and all investments in debt securities are recorded at fair value. Other investments are carried at cost unless there is an indication of a permanent decline in value.

Unrealized gains and losses are recorded in current year operations as increases or decreases in unrestricted net assets. Dividend, interest, and other investment income is recorded as an increase in unrestricted net assets unless the use is restricted by the donor. Realized gains and losses on dispositions are based on the net proceeds and the amortized cost basis of the securities sold, using the specific identification method, and are classified as temporarily restricted or unrestricted based on donor intent. These realized gains and losses flow through the Foundation's yearly activities.

**Property and equipment**

Property and equipment are stated at cost. Additions, renewals, and betterments that extend the lives of assets are capitalized. Replacements, maintenance, and repairs that do not improve or extend the lives of the respective assets are expensed as incurred. Provisions for depreciation are computed using the straight-line method over the estimated useful lives of the assets.

When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gains or losses are recognized as income for that period.

**Asset retirement obligations**

The Foundation records liabilities equal to the fair value of the estimated cost to retire assets. The asset retirement liability is recorded in the period in which the obligation meets the definition of a liability, which is generally when the asset is placed in service. The Foundation has recorded a liability for the abandonment of the cyclotron assets.

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**1. Summary of activities and accounting policies (continued)**

**Impairment of long-lived assets and long-lived assets to be disposed of**

The Foundation reviews long-lived assets and certain identifiable intangibles for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No impairments have been recognized as of December 31, 2009.

**InterTech Science Park**

In connection with its efforts to create and expand an environment for economic development in Northwest Louisiana, the Foundation is developing a science and technology business park (InterTech Science Park) in an identified area within the City of Shreveport that is in proximity to three healthcare organizations. The activities consist of business incubation, programmatic support, financial incentives, and the purchase of land and buildings and redevelopment of the area into a business park that is attractive to existing and start-up science and technology businesses. This may include renovation of existing facilities or construction of new facilities for sale or lease to prospective companies.

**Costs of borrowing**

Financing costs are amortized over the period that the related obligation is outstanding.

**Professional liability claims**

The Foundation maintains insurance for protection from losses resulting from professional liability claims. The policy is of the claims-made type. The Foundation has not experienced material losses from professional liability claims in the past. No accrual for losses has been established.

**Contributions**

Contributions received are recorded as unrestricted, temporarily restricted, or permanently restricted support, depending on the existence or nature of any donor restrictions. All donor-restricted support is reported as an increase in temporarily or permanently restricted net assets depending on the nature of the restriction. When a restriction expires (that is, when a stipulated time restriction ends or purpose restriction is accomplished), temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statements of activities as net assets released from restrictions.

Unconditional promises to give are recognized as revenue in the period received. Promises to give are recorded at realizable value if they are expected to be collected in one year and at fair value if they are expected to be collected in more than one year.

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

1. **Summary of activities and accounting policies** (continued)

**Local government operating grants**

In October of 1997, the voters of Caddo Parish renewed, for a ten year period, a special tax levy by the Caddo Parish Commission (CPC) of two mills on all property subject to taxation for the purpose of economic development through the Biomedical Research Foundation of Northwest Louisiana. In October of 2001, the voters of Caddo Parish approved the CPC's plan to rededicate a portion of the millage to public works and extended it through 2017. The accompanying consolidated financial statements include revenues of \$2,275,001 and \$2,250,000 for the years ended December 31, 2009 and 2008, respectively, for amounts the Foundation has applied for and the CPC has approved.

**Positron Emission Tomography (PET)**

The Foundation has agreements with third-party payors that provide for payments to the Foundation at amounts different from its established rates. PET revenues are reported at the estimated net realizable amounts from patients, third-party payors, and others for services rendered.

**Temporarily and permanently restricted net assets**

Temporarily restricted net assets are those whose use by the Foundation has been limited by donors to a specific time period or purpose. Permanently restricted net assets have been restricted by donors to be maintained by the Foundation in perpetuity.

**Income taxes**

The Foundation has been recognized by the Internal Revenue Service as a not-for-profit organization as described in Section 501(c)(3) of the Internal Revenue Code and is exempt from federal income taxes pursuant to Section 501(a) of the Internal Revenue Code. Accordingly, no provision for income taxes has been made.

The Fund adopted the recent accounting guidance related to accounting for uncertainty in income taxes, which sets out a consistent framework to determine the appropriate level of tax reserves to maintain for uncertain tax positions. The Foundation has evaluated its position regarding the accounting for uncertain income tax positions. A tax position that meet the more-likely-than-not recognition threshold is initially and subsequently measured as the largest amount of tax benefit that has a greater than 50 percent likelihood of being realized upon settlement with a taxing authority that has full knowledge of all relevant information. The determination of whether or not a tax position has met the more-than-likely-than-not recognition threshold considers the facts, circumstances, and information available at the reporting date and is subject to management's judgment. Changes in the recognition or measurement are reflected in the period in which the change in judgment occurs.

With few exceptions, the statute of limitations for the examination of the Foundation's income tax returns is generally 3 years from the due date of the tax return including extensions. The tax years open for assessment are the years ending on or after December 31, 2006.

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

1. **Summary of activities and accounting policies** (continued)

**Statements of cash flows**

For purposes of the statements of cash flows, cash and cash equivalents includes operating and restricted funds on deposit at various financial institutions.

**Environmental obligations**

A provision for environmental obligations is charged to expense when the Foundation's liability for an environmental assessment and/or cleanup is probable and the cost can be reasonably estimated. Related expenditures are charged against the accrued liability.

**Concentrations of credit risk**

The Foundation maintains its cash in bank deposit accounts at various financial institutions. The balances, at times, may exceed federally insured limits. Management believes the credit risk associated with these deposits is minimal.

**Recent accounting pronouncements**

Effective July 1, 2009, the Foundation adopted the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) as the single source of authoritative accounting principles generally accepted in the United States of America (U.S. GAAP). All guidance in the Codification carries an equal level of authority. After the effective date of the Codification, all nongrandfathered accounting literature not included in the Codification is superseded and deemed nonauthoritative. FASB will issue *Accounting Standards Updates* (ASUs), which will serve to update FASB ASC, provide background information about the guidance and provide the basis for conclusions on the changes to FASB ASC. FASB ASC is not intended to change U.S. GAAP.

**Reclassifications**

Certain amounts in the 2008 financial statements have been reclassified to conform to the current year presentation.

2. **Unconditional promises to give**

Unconditional promises to give at December 31, 2009 and 2008, are summarized as follows:

	<u>2009</u>	<u>2008</u>
Unconditional contributions expected to be collected in:		
Less than one year	\$ 126,175	\$ 76,100
Two to five years	<u>153,075</u>	<u>159,150</u>
	279,250	235,250
Less: allowances for doubtful accounts	<u>( 11,157)</u>	<u>( 11,157)</u>
Net unconditional promises to give	<u>\$ 268,093</u>	<u>\$ 224,093</u>

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**3. Accounts receivable**

Accounts receivable consisted of the following at December 31, 2009 and 2008:

	<u>2009</u>	<u>2008</u>
Due from the State of Louisiana and EDA	\$ 79,416	\$ 139,843
Rent receivables	88,848	71,737
Positron Emission Tomography (PET), net	656,700	832,552
Radiopharmaceutical Distribution, net	204,487	135,527
Loans receivable (see below)	220,000	100,000
Other	139,513	194,761
	<u>\$ 1,388,964</u>	<u>\$ 1,474,420</u>

In December of 2004, the Fund loaned \$100,000 to VC Experts.com, Inc. (VC Experts). The convertible promissory note bears interest at 8.00% and matures on December 15, 2011. In accordance with the terms of the promissory note, the Fund has the right to convert the note receivable into cash or common stock of VC Experts.

In June of 2009, the Partnership loaned \$120,000 to Embera Neuro Therapeutics, Inc. (ENT). The convertible promissory note bears interest at a variable rate (5.25% at December 31, 2009) and matures on June 9, 2014. In accordance with the terms of the promissory note, the Partnership has the right to convert the note receivable into cash or common stock of ENT.

**4. Investments**

Investments at December 31, 2009 and 2008 consisted of the following:

	<u>2009</u>	<u>2008</u>
Mutual funds	\$ 5,174,787	\$ 3,573,608
Common stock	120,000	120,000
Limited partnership interests	246,394	246,394
	<u>\$ 5,541,181</u>	<u>\$ 3,940,002</u>

Following is the composition of investment revenues (losses) for the years ended December 31, 2009 and 2008:

	<u>2009</u>	<u>2008</u>
Dividends, interest, and realized gains (losses)	(\$ 684,054)	\$ 502,867
Unrealized gain (loss) on investments	1,643,183	( 2,268,678)
	959,129	( 1,765,811)
Other investment revenues	494,900	-
	<u>\$ 1,454,029</u>	<u>(\$ 1,765,811)</u>

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**5. Property and equipment**

The composition of property and equipment at December 31, 2009 and 2008 was as follows:

<u>Assets</u>	<u>Estimated useful lives</u>	<u>2009</u>	<u>2008</u>
Land	-----	\$ 6,390,588	\$ 5,719,975
Building and improvements	4 - 40 years	56,574,265	56,506,874
Furniture and fixtures / Equip	5 - 20 years	<u>21,659,646</u>	<u>21,463,482</u>
		84,624,499	83,690,331
Less accumulated depreciation		<u>( 34,291,341)</u>	<u>( 32,051,498)</u>
Property and equipment, net		<u>\$ 50,333,158</u>	<u>\$ 51,638,833</u>

Included in these amounts is property that is being held for lease or future development. These assets are comprised of land and buildings. The total carrying values of these assets were approximately \$36,000,000 at both December 31, 2009 and 2008.

Depreciation expense totaled \$2,239,844 and \$2,197,248 for the years ended December 31, 2009 and 2008, respectively.

**6. Long-term debt**

On March 1, 2004, the Foundation (the obligor) entered into a Master Financing Agreement with GE Capital Public Finance, Inc. (the lender) and the Louisiana Public Facilities Authority (the issuer). In accordance with the terms of this agreement, the Issuer issued bonds to the lender, and the lender lent the bond proceeds to the Foundation for the purchase of identified equipment.

During the year ended December 31, 2004, the Foundation borrowed approximately \$5,726,000 of the \$15,000,000 available under the Master Financing Agreement. Of these amounts borrowed, approximately \$3,620,000 was used to retire outstanding indebtedness.

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

6. Long-term debt (continued)

Notes payable at December 31, 2009 and 2008 were as follows:

	<u>2009</u>	<u>2008</u>
<i>Notes payable:</i>		
Note payable to bank at 6.80%; secured by property; due in monthly payments of \$3,910 through November 18, 2011; remaining balance due December 18, 2011	\$ 259,279	\$ 287,204
Note payable to an individual at 7.00%; secured by property; due in monthly payments of \$1,483 through October of 2017	106,219	116,198
Note payable to an individual at 7.00%; secured by property; due in monthly payments of \$1,483 through October of 2017	106,219	116,198
<i>Master financing agreement:</i>		
Schedule #1 dated March 1, 2004, in the original amount of \$4,599,611 at 4.25%; secured by equipment; due in monthly installments of \$85,309 through April 1, 2009	-	254,171
Schedule #2 dated March 1, 2004, in the original amount of \$1,126,264 at 4.50%; secured by equipment; due in monthly installments of \$21,018 through April 1, 2009	-	62,583
	<u>\$ 471,717</u>	<u>\$ 836,354</u>

Revenue bonds payable at December 31, 2009 and 2008 were as follows:

	<u>2009</u>	<u>2008</u>
<i>Revenue bonds:</i>		
Revenue bonds payable, net of discounts of \$53,264 and \$69,800 at December 31, 2009 and 2008, respectively, at interest rates ranging from 7.30% to 7.75%; secured by lease payments; due in installments through June 15, 2015	<u>\$ 11,316,736</u>	<u>\$ 12,755,200</u>



**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

6. Long-term debt (continued)

The revenue bonds were used to finance the cost of land acquisition, construction, equipping of facilities, and other capital expenditures in support of the InterTech Science Park. The bonds are limited and special revenue obligations of the Louisiana Local Government Environmental Facilities and Community Development Authority. The bonds are secured by an assignment of the revenue generated by the lease of the Virginia K. Shehee Biomedical Research Institute building to the Board of Supervisors of the Louisiana State University and Agricultural and Mechanical College. Cash of approximately \$100,000 at December 31, 2009 and 2008 is restricted for payment of the Foundation's share of operating and maintenance expenses for the building.

The revenue bond discount is being amortized over the life of the bonds. Amortization of bond discount was \$16,536 and \$19,281 for the years ended December 31, 2009 and 2008, respectively.

The long-term debt obligations (notes payable and revenue bonds payable) are scheduled to mature during the years ended December 31<sup>st</sup> as follows:

<u>Year ending</u> <u>December 31<sup>st</sup></u>	<u>Amount</u>
2010	\$ 1,609,500
2011	1,932,154
2012	1,834,464
2013	1,976,233
2014	2,133,129
Thereafter	<u>2,356,237</u>
	11,841,717
Less: unamortized discount	( <u>53,264</u> )
	<u>\$ 11,788,453</u>

The Foundation incurred interest expenses of approximately \$1,040,000 and \$1,184,000 for the years ended December 31, 2009 and 2008, respectively.

The Foundation maintains a \$4,000,000 line-of-credit with a national financial institution. This line-of-credit is secured by investments of the Foundation and bears interest at the 30 day LIBOR rate plus 2.25% (2.50% and 4.15% at December 31, 2009 and 2008, respectively). The Foundation paid off the line-of-credit, which had a balance of \$266,827 at December 31, 2008, during the year ended December 31, 2009.

As part of the revenue bond loan agreement and the Master Financing Agreement, the Foundation has agreed to comply with certain covenants. These consist, primarily, of reporting requirements, restrictions on additional debt and security interests, maintenance of its tax-exempt status, maintenance of its facilities, and other administrative requirements.

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**7. Annuities payable**

The Foundation receives donations through split-interest agreements with contributors. These split-interest agreements specify that the donation is made in return for an individual or joint annuity for the remaining lives of the designees. The difference between the contribution and the liability under the annuity is recognized as revenue in the year received. Upon death, the remaining liability, if any, is recognized as revenue. The Foundation did not receive any such donations during the two year period ended December 31, 2009. The balances of all annuities payable at December 31, 2009 and 2008 were \$31,026 and \$38,526, respectively. The liabilities were calculated using discount rates between 7.0% and 6.2%, and were adjusted for changes in life expectancies during the year ended December 31, 2007.

**8. Net assets**

Temporarily restricted net assets were restricted for the following specific operating purposes at December 31, 2009 and 2008:

	<u>2009</u>	<u>2008</u>
SMART program	\$ 13,334	\$ 30,305
Medical Home Project	-	346,548
Cancer research	113,538	105,388
Biostart	56,296	54,677
Other	<u>106,504</u>	<u>54,963</u>
	<u>\$ 289,672</u>	<u>\$ 591,881</u>

Net assets which were released from restrictions during the years ended December 31, 2009 and 2008, due to the Foundation making payments were as follows:

	<u>2009</u>	<u>2008</u>
SMART program	\$ 34,471	\$ 28,699
Medical Home Project	346,548	1,266,660
Biotech Academy	6,530	39,960
Biostart	68,281	-
Other	<u>9,512</u>	<u>32,054</u>
	<u>\$ 465,342</u>	<u>\$ 1,367,373</u>

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

8. Net assets (continued)

Permanently restricted net assets at December 31, 2009 and 2008 consisted of endowment funds the principal of which is permanently restricted and the income of which is unrestricted except for amounts restricted for repair, maintenance, and upgrades of scientific equipment donated by the Foundation to LSUHSC-S.

The Foundation has established prudent investments and spending policies with the objective of maintaining the purchasing power of its endowed net assets in perpetuity and to provide a stable level of support. In an effort to achieve this objective, the Foundation's asset allocation strategy is periodically reviewed and adjusted to maximize return while limiting risk.

A summary of endowed net assets as of December 31, 2009 and 2008 as well as changes in endowed net assets for the years ended December 31, 2009 and 2008, are as follows:

	<u>2009</u>	<u>2008</u>
Balance - beginning of the year	\$ 1,840,953	\$ 1,812,998
Contributions	100	337,205
Withdrawal of donor restrictions	( 32,272)	( 309,250)
Balance - end of the year	<u>\$ 1,808,781</u>	<u>\$ 1,840,953</u>

9. Rental revenues

During the year ended December 31, 1994, the Foundation entered into a cooperative endeavor agreement with the Board of Supervisors of Louisiana State University and Agricultural College (LSU). This agreement sets forth, in part, the terms of the lease of eight of the ten floors of the Virginia K. Shehee Biomedical Research Institute to LSU. During March of 2000, a new lease was entered into that requires the payment of a base rent of \$2,445,000 per year plus the first \$585,000 of certain operating expenses, until June 30, 2015; the base rent will be adjusted every 3 years for changes in the consumer price index. In accordance with the terms of this agreement, the Foundation recorded rental revenues of approximately \$3,600,000 relating to this lease for the years ended December 31, 2009 and 2008, respectively.

The future minimum lease payments expected to be received from the lease with LSU as well as additional operating leases for office and laboratory facilities and real property, during the next five years is as follows:

<u>Year ending</u> <u>December 31<sup>st</sup></u>	<u>Amount</u>
2010	\$ 3,990,405
2011	3,800,338
2012	3,762,992
2013	3,762,992
2014	<u>3,669,392</u>
	<u>\$ 18,986,119</u>

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**10. Federal and state grants**

The Foundation was awarded a hazardous cleanup assistance grant from the Environmental Protection Agency. The federal grant was awarded to assist with the cleanup of property and to conduct meaningful public involvement regarding the cleanup and reuse of the property. Revenues earned from this grant totaled approximately \$145,200 and \$93,500 for the years ended December 31, 2009 and 2008, respectively.

The Foundation was also awarded and fully expensed grants totaling approximately \$617,000 and \$689,000 from the Louisiana Department of Economic Development to equip and operate the wet laboratory incubator facility during the years ended December 31, 2009 and 2008, respectively.

In February of 2007, the Foundation was awarded a federal grant in the amount of \$2,400,000 from the Department of Health and Human Services for the implementation of the *Northwest Louisiana Health Care Initiative: Applying a Collaborative Medical Home Concept in Rural and Inner City Northwest Louisiana Project*.

**11. Radiopharmaceutical revenues**

The Foundation has a limited number of customers for the radiopharmaceuticals that it produces to sell to third parties. The three largest customers comprised approximately 57% and 52% of the sales during the years ended December 31, 2009 and 2008, respectively. Should one or more of the customers discontinue the purchase of radiopharmaceuticals from the Foundation, this could have a material effect on radiopharmaceuticals revenues in future periods.

**12. Retirement benefit plan**

Retirement benefits are provided for substantially all employees through a defined contribution plan which is sponsored by the American Chamber of Commerce Executives. The retirement benefits are based on the actual value of the employees' account balances at the time of retirement. Employees must be twenty-one years of age and must have completed one year of service before they become eligible to participate in the plan. Employees attain a 20% vested interest in the plan after two years of employment increasing to 40%, 60%, 80%, and 100% over the following four years of employment. Contributions to the plan are based on the participants' salaries. The employer's contributions were approximately \$323,000 and \$258,000 for the years ended December 31, 2009 and 2008, respectively.

The Foundation also has a 403(b) annuity plan. No employer contributions are required for this plan.

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

13. **Fair Value of financial instruments**

In accordance with the *Fair Value Measurements and Disclosure* topic of FASB ASC, disclosure of fair value information about financial instruments, whether or not recognized in the statements of financial position is required. Fair value of a financial instrument is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. In cases where quoted market prices are not available, fair values are based on estimates using present value or other valuation techniques. Those techniques are significantly affected by the assumptions used, including the discount rate and estimates of future cash flows. Accordingly, the fair value estimates may not be realized in an immediate settlement of the instruments. Therefore, the aggregate fair value amounts presented do not represent the underlying value of the Foundation.

The recent fair value guidance provides a consistent definition of fair value, which focuses on exit price in an orderly transaction (that is, not a forced liquidation or distressed sale) between market participants at the measurement date under current market conditions. If there has been a significant decrease in the volume and level of activity for the asset or liability, a change in valuation technique or the use of multiple valuation techniques may be appropriate. In such instances, determining the price at which willing market participants would transact at the measurement date under current market conditions depends on the facts and circumstances and requires use of significant judgment. The fair value is a reasonable point within the range that is most representative of fair value under current market conditions.

**Fair Value Hierarchy**

In accordance with this guidance, the Foundation groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.

- Level 1 - valuation is based on quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.
- Level 2 - valuation is based on inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly. The valuation may be based on quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability.
- Level 3 - valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which determination of fair value requires significant management judgment or estimation.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

13. Fair Value of financial instruments (continued)

*Fair Value of Assets Measured on a Recurring Basis*

The Foundation's investments are measured on a recurring basis through estimates and assumptions made by management. Our level three assets within investments include investments in common stocks which are not actively traded and limited partnership interests. We value level 3 investments using inputs which include discounted cash flow models. Unobservable inputs used in these models are significant to the fair value of the investments.

The following table presents for each of the fair-value hierarchy level the Foundation's financial assets and liabilities that are measured at fair value on a recurring basis:

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Investments - December 31 2009	\$ <u>5,174,787</u>	\$ <u>-</u>	\$ <u>366,394</u>
Investments - December 31 2008	\$ <u>3,573,608</u>	\$ <u>-</u>	\$ <u>366,394</u>

14. Commitments and contingencies

The Foundation receives a portion of its revenues from government grants and contracts which are subject to audit by the federal government. The ultimate determination of amounts received under these programs generally is based upon allowable costs reported to and subject to audit by the government. Until such audits have been completed and final settlement reached, there exists a contingency to refund any amount received in excess of allowable costs. Management is of the opinion that no material liability will result from such audits.

The Foundation receives, directly or indirectly, a portion of its revenues from government grants and tax millages. Although the Foundation does not anticipate a material change in these revenues, there is a possibility that the continued funding of these revenues at current levels could be altered in the future.

In 2000, the Foundation pledged to support research at LSU in the amount of \$500,000 (with CPI adjustments every third year) each year until 2015. The pledge is contingent upon LSU's fulfillment of certain obligations including having made all required lease payments as well as providing an annual five-year plan for expenditure of the funds which is acceptable to the Foundation. As such, the portion of the pledge relating to future years has not been recorded in the accompanying consolidated financial statements.

During the year ended December 31, 2009, the Foundation entered into a construction contract related to the BioSpace 1 Moonbot Studios. The contract had an outstanding commitment of approximately \$1,884,000 at December 31, 2009.

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**Commitments and contingencies (continued)**

The Foundation has been notified by the Louisiana Department of Environmental Quality (LDEQ) that one piece of property owned by the Foundation is located on the site of a former creosoting company and that environmental contamination has been confirmed. Based on information from LDEQ, all former business entities of the company responsible for the contamination are bankrupt or otherwise defunct. The Foundation and other affected landowners have been asked by the LDEQ to perform a "Site Investigation" to determine the extent of contamination. In management's opinion, environmental issues will not have a material impact on the net assets of the Foundation. No accrual has been made in these consolidated financial statements for environmental liabilities due to the Foundation being unable to estimate an amount for future investigation or remediation or the amount of grants that may be available to cover such costs.

**15. Subsequent events**

Management has evaluated subsequent events through April 28, 2010, the date that the financial statements were available to be issued, and determined that no additional disclosures are necessary.

**INDEPENDENT AUDITORS' REPORT ON INTERNAL CONTROL OVER  
FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED  
ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH  
GOVERNMENT AUDITING STANDARDS**

Board of Directors  
Biomedical Research Foundation of Northwest Louisiana  
Shreveport, Louisiana

We have audited the consolidated financial statements of the Biomedical Research Foundation of Northwest Louisiana and its subsidiaries (the Foundation) as of and for the year ended December 31, 2009, and have issued our report thereon dated April 28, 2010. We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States.

**Internal Control Over Financial Reporting**

In planning and performing our audit, we considered the Foundation's internal control over financial reporting as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control over financial reporting. Accordingly, we do not express an opinion of the effectiveness of the Foundation's internal control over financial reporting.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A material weakness is a deficiency, or combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the financial statements will not be prevented, or detected and corrected on a timely basis.

Our consideration of the internal control over financial reporting was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in the internal control that might be deficiencies, significant deficiencies, or material weaknesses. We did not identify any deficiencies in internal control over financial reporting that we consider to be material weaknesses, as defined above.

**Compliance and Other Matters**

As part of obtaining reasonable assurance about whether the Foundation's consolidated financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



This report is intended solely for the information and use of the Board of Directors and management of the Biomedical Research Foundation of Northwest Louisiana and is not intended to be and should not be used by anyone other than these specified parties. However, under Louisiana Revised Statute 24:513, this report is distributed by the Legislative Auditor as a public document.

*Portlathuaita: Netterville*

Baton Rouge, Louisiana  
April 28, 2010

**INDEPENDENT AUDITORS' REPORT ON COMPLIANCE WITH REQUIREMENTS APPLICABLE TO  
EACH MAJOR PROGRAM AND ON INTERNAL CONTROL OVER COMPLIANCE IN  
ACCORDANCE WITH OMB CIRCULAR A-133**

Board of Directors  
Biomedical Research Foundation of Northwest Louisiana  
Shreveport, Louisiana

**Compliance**

We have audited the compliance of the Biomedical Research Foundation of Northwest Louisiana with the types of compliance requirements described in the *U. S. Office of Management and Budget (OMB) Circular A-133 Compliance Supplement* that are applicable to its major federal programs for the year ended December 31, 2009. The Biomedical Research Foundation of Northwest Louisiana's major federal programs are identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs. Compliance with the requirements of laws, regulations, contracts, and grants applicable to its major federal programs is the responsibility of the Biomedical Research Foundation of Northwest Louisiana's management. Our responsibility is to express an opinion on the Biomedical Research Foundation of Northwest Louisiana's compliance based on our audit.

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and OMB Circular A-133, *Audits of States, Local Governments, and Non-Profit Organizations*. Those standards and OMB Circular A-133 require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the Foundation's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. Our audit does not provide a legal determination of the Foundation's compliance with those requirements.

In our opinion the Biomedical Research Foundation of Northwest Louisiana complied, in all material respects, with the requirements referred to above that are applicable to its major federal programs for the year ended December 31, 2009.

**Internal Control Over Compliance**

The management of the Biomedical Research Foundation of Northwest Louisiana is responsible for establishing and maintaining effective internal control over compliance with requirements of laws, regulations, contracts, and grants applicable to federal programs. In planning and performing our audit, we considered the Foundation's internal control over compliance with requirements that could have a direct and material effect on a major federal program in order to determine our auditing procedures for the purpose of expressing our opinion on compliance and to test and report on internal control over compliance in accordance with OMB Circular A-133, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the Foundation's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be deficiencies, significant deficiencies, or material weaknesses. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above.

#### **Schedule of Expenditures of Federal Awards**

We have audited the consolidated financial statements of the Biomedical Research Foundation of Northwest Louisiana as of and for the year ended December 31, 2009, and have issued our report thereon dated April 28, 2010. Our audit was performed for the purpose of forming an opinion on the basic financial statements taken as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by OMB Circular A-133 and is not a required part of the basic financial statements. Such information has been subjected to the auditing procedures applied in the audit of the basic financial statements and, in our opinion, is fairly stated, in all material respects, in relation to the basic financial statements taken as a whole.

This report is intended for the information and use of the Board of Directors and management of the Biomedical Research Foundation of Northwest Louisiana, federal and state awarding agencies, and the Louisiana Legislative Auditor and is not intended to be and should not be used by anyone other than these specified parties. However, under Louisiana Revised Statute 24:513, this report is distributed by the Legislative Auditor as a public document.

*Postlethwaite: Wettersville*

Baton Rouge, Louisiana  
April 28, 2010

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS**  
**FOR THE YEAR ENDED DECEMBER 31, 2009**

<b><u>FEDERAL DEPARTMENT/PASS-THROUGH ENTITY/PROGRAM</u></b>	<b><u>CFDA #</u></b>	<b><u>Grant #</u></b>	<b><u>EXPENDED</u></b>
<b><u>United States Department of Health and Human Services</u></b>			
Cooperative Agreements to Improve the Health Status of Minority Populations - passed through the Auxiliary to the National Medical Association, Inc.	93.004	MPCMP051004-2-07	\$ 346,536 <u>346,536</u>
<b><u>United States Environmental Protection Agency</u></b>			
Brownfield Assessment and Cleanup	66.818	BF 96633401-0	7,389
Cooperative agreement		BF 96633601-0	134,631
		BF 96693201-0	3,262
			<u>145,282</u>
<b><u>United States Department of Housing and Urban Development</u></b>			
Economic Development Initiative - Special Project Neighborhood Initiative and Miscellaneous Grants	14.251	B03SPLA0295	107,526
		B03SPLA0296	380,098
			<u>487,624</u>
<b><u>United States Department of Commerce</u></b>			
Economic Development Administration Public Works and Economic Development Facilities	11.300	08-01-03873	78,648
			<u>78,648</u>
Total Expenditures			\$ <u>1,058,090</u>

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**NOTES TO SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS**  
**YEAR ENDED DECEMBER 31, 2009**

**Note A - Basis of presentation**

The accompanying schedule of expenditures of federal awards includes the federal grant activity of the Biomedical Research Foundation of Northwest Louisiana and its subsidiaries and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of OMB Circular A-133, *Audits of States, Local Governments, and Non-Profit Organizations*. Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in the preparation of, the basic financial statements.

**Note B - Reconciliation to financial statements**

The expenditures listed in the accompanying schedule of expenditures of federal awards relating to the grants with the United States Department of Health and Human Services, the United States Environmental Protection Agency, and the United States Department of Commerce are reported as expenses in the Foundation's consolidated financial statements as of and for the year ended December 31, 2009.

The expenditures listed in the accompanying schedule of expenditures of federal awards relating to the grant with the United States Department of Housing and Urban Development are reported as capital expenditures / additions to property and equipment in the Foundation's consolidated financial statements as of and for the year ended December 31, 2009.

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**SCHEDULE OF FINDINGS AND QUESTIONED COSTS**  
**YEAR ENDED DECEMBER 31, 2009**

**A. Summary of Auditors' Results**

*Financial Statements*

Type of auditor's report issued: *Unqualified*

Internal Control over Financial Reporting:

- Material weakness(es) identified? \_\_\_\_\_ yes      x   no
- Significant deficiency(ies) identified that are not considered to be material weaknesses? \_\_\_\_\_ yes      x   none reported

Noncompliance material to financial statements noted?

\_\_\_\_\_ yes      x   no

*Federal Awards*

Internal control over major programs:

- Material weakness(es) identified? \_\_\_\_\_ yes      x   no
- Significant deficiency(ies) identified that are not considered to be material weaknesses? \_\_\_\_\_ yes      x   none reported

Type of auditor's report issued on compliance for major programs: *Unqualified*

Any audit findings disclosed that are required to be reported in accordance with section 510(a) of Circular A-133?

\_\_\_\_\_ yes      x   no

Identification of major program:

**CFDA Numbers**

**Name of Federal Program or Cluster**

14.251

Economic Development Initiative -  
Special Project Neighborhood Initiative  
and Miscellaneous Grants

The threshold for distinguishing types A & B programs was program expenditures exceeding \$300,000.

The Biomedical Research Foundation of Northwest Louisiana was determined to be a low risk auditee.

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**SCHEDULE OF FINDINGS AND QUESTIONED COSTS**  
**YEAR ENDED DECEMBER 31, 2009**

**B. Findings - Financial Statement Audit**

None

**C. Findings and Questioned Costs - Major Federal Award Programs**

None

**BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA**  
**SHREVEPORT, LOUISIANA**

**SUMMARY SCHEDULE OF PRIOR YEAR FINDINGS AND QUESTIONED COSTS**  
**YEAR ENDED DECEMBER 31, 2009**

**A. Findings - financial statement audit:**

(1) None